

**Clinical trial results:****A Multicenter, Double blind, Vehicle-controlled, Randomized Study of Photodynamic Therapy (PDT) With Metvix 160 mg/g Cream and Aklilite CL128 LED Light in Patients With Multiple Actinic Keratoses on the Face and/or Scalp****Summary**

EudraCT number	2005-005015-13
Trial protocol	DE
Global end of trial date	23 January 2007

Results information

Result version number	v1 (current)
This version publication date	07 July 2022
First version publication date	07 July 2022

Trial information**Trial identification**

Sponsor protocol code	PC T405/05
-----------------------	------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00304239
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Galderma R&D SNC
Sponsor organisation address	Les Templiers, 2400 route des colles, Biot, France, 06410
Public contact	CTA Coordinator, Galderma R&D SNC, +33 (0)493-95-70-85, cta.coordinator@galderma.com
Scientific contact	CTA Coordinator, Galderma R&D SNC, +33 (0)493-95-70-85, cta.coordinator@galderma.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	23 January 2007
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	23 January 2007
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The main objective of this trial was to compare the subject complete response rate of Metvix® Photodynamic Therapy (PDT) to that of vehicle PDT 3 months after last treatment in subjects with multiple Actinic Keratoses (AK) lesions on the face and/or scalp.

Protection of trial subjects:

The study was conducted in accordance with the principles of the Declaration of Helsinki, 1964, as amended in Edinburgh, United Kingdom (UK), 2000, and in compliance with the International Conference on Harmonization (ICH) guidelines for Good Clinical Practice (GCP), as described in the European Medicines Agency (EMA) Note for Guidance on Good Clinical Practice, committee for Proprietary Medicinal Products, CPMP/ICH/135/95, in operation 17 January 1997, and applicable regulatory requirements.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	13 March 2006
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Germany: 83
Country: Number of subjects enrolled	United States: 48
Worldwide total number of subjects	131
EEA total number of subjects	83

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	37

From 65 to 84 years	86
85 years and over	8

Subject disposition

Recruitment

Recruitment details:

The study was conducted at 12 centers in Germany and the United States between 13 March 2006 to 23 January 2007.

Pre-assignment

Screening details:

A total of 131 subjects were enrolled and received treatment in this study.

Period 1

Period 1 title	Overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
Arm title	Metvix-PDT

Arm description:

Metvix (methyl aminolevulinat hydrochloride) 160 milligrams per gram (mg/g) cream was applied to face and or scalp at Day 0 and at Day 7 where other therapies were unacceptable or considered medically less appropriate.

Arm type	Experimental
Investigational medicinal product name	Metvix 160 mg/g Cream
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

Metvix 160 mg/g Cream was applied for 3 hours with occlusive dressing, and illumination with non-coherent red light using the Aktelite CL128 lamp, with a total light dose 37 Joule per square centimeter (J/cm^2). All eligible lesions on the subject were treated twice with an interval of 1 week between treatments.

Arm title	Vehicle-PDT
------------------	-------------

Arm description:

Vehicle cream was applied to face and or scalp at Day 0 and at Day 7 where other therapies were unacceptable or considered medically less appropriate.

Arm type	Placebo
Investigational medicinal product name	Vehicle-PDT
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

Vehicle Cream was applied for 3 hours with occlusive dressing, and illumination with non-coherent red light using the Aktelite® CL128 lamp, with a total light dose 37 J/cm^2 . All eligible lesions on the subject were treated twice with an interval of 1 week between treatments.

Number of subjects in period 1	Metvix-PDT	Vehicle-PDT
Started	73	58
Completed	56	58
Not completed	17	0
Adverse event	2	-
Protocol deviation	15	-

Baseline characteristics

Reporting groups

Reporting group title	Metvix-PDT
-----------------------	------------

Reporting group description:

Metvix (methyl aminolevulinate hydrochloride) 160 milligrams per gram (mg/g) cream was applied to face and or scalp at Day 0 and at Day 7 where other therapies were unacceptable or considered medically less appropriate.

Reporting group title	Vehicle-PDT
-----------------------	-------------

Reporting group description:

Vehicle cream was applied to face and or scalp at Day 0 and at Day 7 where other therapies were unacceptable or considered medically less appropriate.

Reporting group values	Metvix-PDT	Vehicle-PDT	Total
Number of subjects	73	58	131
Age categorical Units: Subjects			

Age continuous Units: years arithmetic mean standard deviation	70.0 ± 8.4	67.0 ± 10.4	-
Gender categorical Units: Subjects			
Female	13	13	26
Male	60	45	105
Race/Ethnicity, Customized Units: Subjects			
Caucasian	73	58	131

End points

End points reporting groups

Reporting group title	Metvix-PDT
Reporting group description: Metvix (methyl aminolevulinic acid hydrochloride) 160 milligrams per gram (mg/g) cream was applied to face and or scalp at Day 0 and at Day 7 where other therapies were unacceptable or considered medically less appropriate.	
Reporting group title	Vehicle-PDT
Reporting group description: Vehicle cream was applied to face and or scalp at Day 0 and at Day 7 where other therapies were unacceptable or considered medically less appropriate.	

Primary: Percentage of Subjects With Complete Response

End point title	Percentage of Subjects With Complete Response ^[1]
End point description: Subject complete response was defined as the percentage of subjects with all treated lesions that were assessed as clear and/or on face and scalp at 3 months after treatment determined by clinical assessment (visual inspection and palpation). Percentage of subjects with complete response at 3 months after treatment was reported. The analysis was performed on the intention-to-treat (ITT) population which consisted of all subjects that were randomized and for whom any aspect of treatment with either Metvix-PDT or Vehicle-PDT was initiated.	
End point type	Primary
End point timeframe: Up to 3 months	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned to be analyzed for this endpoint.

End point values	Metvix-PDT	Vehicle-PDT		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	57	58		
Units: Percentage of subjects				
number (confidence interval 95%)	68.4 (54.8 to 80.1)	6.9 (1.9 to 16.7)		

Statistical analyses

No statistical analyses for this end point

Secondary: Lesion Complete Response

End point title	Lesion Complete Response
End point description: Lesion complete response was defined as the percentage of pre-existing and treated lesions that were assessed as clear on face and scalp 3 months after treatment. Percentage of lesions after 3 months of treatment was reported. The analysis was performed on the ITT population which consisted of all subjects that were randomized and for whom any aspect of treatment with either Metvix-PDT or Vehicle-PDT was initiated.	

End point type	Secondary
End point timeframe:	
Up to 3 months	

End point values	Metvix-PDT	Vehicle-PDT		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	57	58		
Units: Percentage of lesions				
number (not applicable)	83	29		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With at Least One Treatment Site Adverse Events

End point title	Number of Subjects With at Least One Treatment Site Adverse Events
-----------------	--

End point description:

An AE was any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product and which does not necessarily had a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory value), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. Number of subjects with at least one treatment site adverse events were reported. The safety population consisted of all subjects for whom any kind of treatment was initiated.

End point type	Secondary
End point timeframe:	
Up to 3 Months	

End point values	Metvix-PDT	Vehicle-PDT		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	73	58		
Units: Subjects	61	27		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From study drug administration up to 3 Months

Adverse event reporting additional description:

The safety population consisted of all subjects for whom any kind of treatment was initiated.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	8.0
--------------------	-----

Reporting groups

Reporting group title	Metvix® (methyl aminolevulinate hydrochloride)-PDT
-----------------------	--

Reporting group description:

Metvix® 160 milligrams/gram (mg/g) Cream (active IMP) was applied to face/scalp where other therapies were unacceptable or considered medically less appropriate.

Reporting group title	Vehicle-PDT
-----------------------	-------------

Reporting group description:

Vehicle cream was applied to face/scalp where other therapies were unacceptable or considered medically less appropriate.

Serious adverse events	Metvix® (methyl aminolevulinate hydrochloride)-PDT	Vehicle-PDT	
Total subjects affected by serious adverse events			
subjects affected / exposed	6 / 73 (8.22%)	3 / 58 (5.17%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Investigations			
Hospitalization for coronary cateterization			
subjects affected / exposed	1 / 73 (1.37%)	0 / 58 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Cerebral Concussion			
subjects affected / exposed	1 / 73 (1.37%)	0 / 58 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Surgical and medical procedures			
Basal cell carcinoma nose surgery			

subjects affected / exposed	1 / 73 (1.37%)	0 / 58 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Surgery of squamous cell carcinoma right cheek			
subjects affected / exposed	1 / 73 (1.37%)	0 / 58 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Re-surgery of squamous cell carcinoma right cheek			
subjects affected / exposed	1 / 73 (1.37%)	0 / 58 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lentigo maligna surgery			
subjects affected / exposed	1 / 73 (1.37%)	0 / 58 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Planned three-step surgery of preexisting squamous cell carcinoma			
subjects affected / exposed	1 / 73 (1.37%)	0 / 58 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Basal cell carcinoma left cheek surgery			
subjects affected / exposed	0 / 73 (0.00%)	1 / 58 (1.72%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Re-surgery and wound suture basal cell carcinoma left cheek			
subjects affected / exposed	0 / 73 (0.00%)	1 / 58 (1.72%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Knee prosthesis right due to arthrosis			
subjects affected / exposed	0 / 73 (0.00%)	1 / 58 (1.72%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Nervous system disorders			
Transient ischaemic attack			
subjects affected / exposed	1 / 73 (1.37%)	0 / 58 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retrograde amnesia and anterograde amnesia due to cerebral concussion			
subjects affected / exposed	1 / 73 (1.37%)	0 / 58 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Inguinal hernia			
subjects affected / exposed	0 / 73 (0.00%)	1 / 58 (1.72%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Metvix® (methyl aminolevulinate hydrochloride)-PDT	Vehicle-PDT	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	62 / 73 (84.93%)	34 / 58 (58.62%)	
Skin and subcutaneous tissue disorders			
Pain of skin			
subjects affected / exposed	40 / 73 (54.79%)	12 / 58 (20.69%)	
occurrences (all)	40	12	
Erythema			
subjects affected / exposed	38 / 73 (52.05%)	3 / 58 (5.17%)	
occurrences (all)	38	3	
Skin burning sensation			
subjects affected / exposed	26 / 73 (35.62%)	12 / 58 (20.69%)	
occurrences (all)	26	12	
Pruritus			
subjects affected / exposed	15 / 73 (20.55%)	2 / 58 (3.45%)	
occurrences (all)	15	2	
Skin discomfort			

subjects affected / exposed occurrences (all)	10 / 73 (13.70%) 10	3 / 58 (5.17%) 3	
Skin exfoliation subjects affected / exposed occurrences (all)	11 / 73 (15.07%) 11	1 / 58 (1.72%) 1	
Scab subjects affected / exposed occurrences (all)	11 / 73 (15.07%) 11	1 / 58 (1.72%) 1	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
04 November 2005	The safety follow-up visit was scheduled 2 weeks after last treatment.
02 May 2006	The protocol was updated to perform the study in Germany and United Kingdom. However, the study was initiated only in Germany. Subsequently, the study was expanded to include 4 centers in the United States and to extend the recruitment period due to slower than expected enrollment in the original German centers.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

None reported

Notes: